Rapport Therapeutics, Inc. (RAPP)Healthcare | Biotechnology | Boston, United States | NasdaqGM
36.27 USD
-0.87
(-2.342%) ⇩
(April 21, 2026, 12:05 p.m.
EDT)
Short-term: ★★★☆☆ | Long-term: ★★☆☆☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 19, 2026, 1:20 a.m. EDT
RAPP is a difficult high-risk venture play where recent monster performance (up ~280% YTD) has coincided with significant insider selling, creating a "crowded trade" risk despite strong analyst upgrades. The stock lacks fundamental safety (negative earnings, no dividend) and faces the typical binary risk of biotech developers awaiting Phase 2a data. While the Price-to-Book ratio above 3.5x suggests the market is pricing in massive success, the recent insider offloading of millions of dollars in shares is a major red flag for sustainability, capping the near-term upside potential. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.089377 |
| AutoARIMA | 0.092151 |
| AutoETS | 0.093000 |
| MSTL | 0.095644 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 26% |
| H-stat | 15.14 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.011 |
| Excess Kurtosis | 0.63 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 2.37 |
| Market Cap | 1,733,450,112 |
| Forward P/E | -8.64 |
| Website | https://www.rapportrx.com |
As of April 19, 2026, 1:20 a.m. EDT: Options sentiment shows high downside protection via May 2026 puts (heavy OI at $30, $35 strikes), indicating a 'high' floor expectation around 30-35 despite the current price of ~39.71. Call flow is skewed towards the money and ITM (40.0, 42.5), suggesting a non-aggressive upside bet. November options are virtually inert with volume exceeding open interest at the ATM ($40 call), hinting at potential supportive buying pressure. Implied volatility is moderate (under 1.2), suggesting a market that believes moderate moves are priced in, but insider selling hasn't spiked IV significantly yet.
| Attribute | Value |
|---|---|
| 52 Week Change | 2.2155845 |
| Address1 | 99 High Street |
| Address2 | Suite 2100 |
| All Time High | 42.269 |
| All Time Low | 6.43 |
| Ask | 45.91 |
| Ask Size | 2 |
| Audit Risk | 7 |
| Average Analyst Rating | 1.1 - Strong Buy |
| Average Daily Volume10 Day | 398,170 |
| Average Daily Volume3 Month | 345,680 |
| Average Volume | 345,680 |
| Average Volume10Days | 398,170 |
| Bid | 26.55 |
| Bid Size | 2 |
| Board Risk | 7 |
| Book Value | 10.145 |
| City | Boston |
| Compensation As Of Epoch Date | 1,735,603,200 |
| Compensation Risk | 9 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 36.27 |
| Current Ratio | 26.173 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 37.13 |
| Day Low | 35.71 |
| Debt To Equity | 2.37 |
| Display Name | Rapport Therapeutics |
| Earnings Timestamp | 1,773,145,800 |
| Earnings Timestamp End | 1,778,157,000 |
| Earnings Timestamp Start | 1,778,157,000 |
| Ebitda | -124,082,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -10.445 |
| Enterprise Value | 1,295,974,912 |
| Eps Current Year | -3.36571 |
| Eps Forward | -4.2 |
| Eps Trailing Twelve Months | -2.86 |
| Esg Populated | 0 |
| Exchange | NGM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 30.3802 |
| Fifty Day Average Change | 5.889801 |
| Fifty Day Average Change Percent | 0.19386972 |
| Fifty Two Week Change Percent | 221.55846 |
| Fifty Two Week High | 42.269 |
| Fifty Two Week High Change | -5.9990005 |
| Fifty Two Week High Change Percent | -0.14192435 |
| Fifty Two Week Low | 7.73 |
| Fifty Two Week Low Change | 28.54 |
| Fifty Two Week Low Change Percent | 3.6921089 |
| Fifty Two Week Range | 7.73 - 42.269 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,717,767,000,000 |
| Float Shares | 30,787,736 |
| Forward Eps | -4.2 |
| Forward P E | -8.635715 |
| Free Cashflow | -54,166,876 |
| Full Exchange Name | NasdaqGM |
| Full Time Employees | 84 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,775,001,600 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.046040002 |
| Held Percent Institutions | 1.0763 |
| Implied Shares Outstanding | 47,792,943 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,024-06-07 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Rapport Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company that focuses on the discovery and development of transformational small molecule medicines for patients suffering from central nervous system (CNS) disorders. The company's lead product candidate is receptor associated protein (RAP)-219, an investigational small molecule that is designed to inhibit TARPy8-containing AMPARs with picomolar affinity for the treatment of focal epilepsy and other CNS disorders, including peripheral neuropathic pain and bipolar disorder. It also develops nicotinic acetylcholine receptor (nAChR) programs, such as a6 nAChR to treat chronic pain and migraine; and a9a10 nAChR for the treatment of hearing/vestibular disorders. The company was formerly known as Precision Neuroscience NewCo, Inc. and changed its name to Rapport Therapeutics, Inc. in October 2022. Rapport Therapeutics, Inc. was incorporated in 2022 and is headquartered in Boston, Massachusetts. |
| Long Name | Rapport Therapeutics, Inc. |
| Market | us_market |
| Market Cap | 1,733,450,112 |
| Market State | REGULAR |
| Max Age | 86,400 |
| Message Board Id | finmb_1828746377 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | -111,483,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 1,777,419,550 |
| Number Of Analyst Opinions | 10 |
| Open | 36.93 |
| Operating Cashflow | -87,473,000 |
| Operating Margins | 0.0 |
| Overall Risk | 8 |
| Payout Ratio | 0.0 |
| Phone | 857 321 8020 |
| Previous Close | 37.14 |
| Price Eps Current Year | -10.77633 |
| Price Hint | 2 |
| Price To Book | 3.57516 |
| Profit Margins | 0.0 |
| Quick Ratio | 25.751 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.09091 |
| Region | US |
| Regular Market Change | -0.86999893 |
| Regular Market Change Percent | -2.342485 |
| Regular Market Day High | 37.13 |
| Regular Market Day Low | 35.71 |
| Regular Market Day Range | 35.71 - 37.13 |
| Regular Market Open | 36.93 |
| Regular Market Previous Close | 37.14 |
| Regular Market Price | 36.27 |
| Regular Market Time | 1,776,787,538 |
| Regular Market Volume | 173,045 |
| Return On Assets | -0.189 |
| Return On Equity | -0.28221 |
| Sand P52 Week Change | 0.34445214 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 47,792,943 |
| Shares Percent Shares Out | 0.0805 |
| Shares Short | 3,849,519 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 3,513,015 |
| Short Name | Rapport Therapeutics, Inc. |
| Short Percent Of Float | 0.1462 |
| Short Ratio | 10.6 |
| Source Interval | 15 |
| State | MA |
| Symbol | RAPP |
| Target High Price | 80.0 |
| Target Low Price | 40.0 |
| Target Mean Price | 53.6 |
| Target Median Price | 50.5 |
| Total Cash | 490,539,008 |
| Total Cash Per Share | 10.264 |
| Total Debt | 11,484,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -2.86 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 25.31345 |
| Two Hundred Day Average Change | 10.956551 |
| Two Hundred Day Average Change Percent | 0.43283513 |
| Type Disp | Equity |
| Volume | 173,045 |
| Website | https://www.rapportrx.com |
| Zip | 2,110 |